Greenleaf Trust Makes New Investment in UiPath Inc. (NYSE:PATH)

Greenleaf Trust bought a new position in UiPath Inc. (NYSE:PATH) in the fourth quarter, Holdings Channel reports. The institutional investor bought 8,735 shares of the healthcare company’s stock, valued at approximately $217,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Royal London Asset Management Ltd. increased its stake in shares of UiPath by 5.9% in the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock worth $2,388,000 after acquiring an additional 7,742 shares during the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in shares of UiPath in the 3rd quarter worth $203,000. Invesco Ltd. increased its stake in shares of UiPath by 2.8% in the 3rd quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock worth $6,830,000 after acquiring an additional 10,863 shares during the last quarter. Symmetry Partners LLC acquired a new stake in shares of UiPath in the 4th quarter worth $205,000. Finally, Toroso Investments LLC increased its stake in shares of UiPath by 196.7% in the 3rd quarter. Toroso Investments LLC now owns 78,189 shares of the healthcare company’s stock worth $1,338,000 after acquiring an additional 51,834 shares during the last quarter. 62.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on PATH shares. JPMorgan Chase & Co. raised UiPath from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $22.00 to $28.00 in a research report on Thursday, March 14th. Wells Fargo & Company raised their price objective on UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 14th. Needham & Company LLC restated a “buy” rating and set a $30.00 target price on shares of UiPath in a report on Wednesday, March 20th. Scotiabank raised their target price on UiPath from $29.00 to $30.00 and gave the company a “sector perform” rating in a report on Thursday, March 14th. Finally, Canaccord Genuity Group raised their target price on UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a report on Friday, March 15th. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $27.41.

Insider Buying and Selling

In related news, CFO Ashim Gupta sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the sale, the chief financial officer now owns 660,762 shares in the company, valued at $14,312,104.92. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 72,000 shares of company stock worth $1,591,360 over the last 90 days. 31.03% of the stock is owned by insiders.

UiPath Trading Up 0.7 %

Shares of PATH opened at $19.69 on Thursday. The stock has a 50-day simple moving average of $22.42 and a 200-day simple moving average of $21.55. UiPath Inc. has a 1 year low of $12.38 and a 1 year high of $27.87.

UiPath (NYSE:PATH) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.10. The firm had revenue of $405.25 million during the quarter, compared to analysts’ expectations of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. As a group, equities analysts predict that UiPath Inc. will post -0.04 earnings per share for the current year.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.